Navigation Links
Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
Date:12/8/2008

NEW YORK and SAN DIEGO, Dec. 8, 2008 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) and Cypress Bioscience, Inc. (Nasdaq: CYPB) today announced positive top-line results from a 1,025 patient, multicenter, double-blind, placebo-controlled phase III study of milnacipran for the management of fibromyalgia. These results, which confirm the findings from the two previous phase III trials, showed that milnacipran demonstrated a highly statistically significant difference to placebo in responder analyses based on a concurrent and clinically meaningful improvement in pain, patient global impression of change, and physical functioning. Comprehensive analyses of the study data will be completed in the coming weeks, and it is anticipated that further results will be presented during 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

Study Background

In this study, designated MLN-MD-03, patients with an established history of fibromyalgia were enrolled at 75 centers in North America and randomized to receive a daily dose of 100 mg of milnacipran (n=516) or placebo (n=509). The design of the double-blind study included a 4 to 6-week dose escalation phase, a 12-week stable-dose treatment phase, and a 2-week discontinuation phase. The primary efficacy endpoints were the proportion of subjects meeting criteria as composite responders based on one of two definitions. In the first co-primary analysis, a patient had to demonstrate simultaneous improvements on both their daily pain ratings (visual analog scale) and on an overall measure of how their fibromyalgia condition had been since the start of the stu
'/>"/>

SOURCE Forest Laboratories, Inc.; Cypress Bioscience, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
2. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
3. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
4. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
5. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
6. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
7. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
8. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
9. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
10. Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
11. Roxane Laboratories, Inc. Updated Launch of Calcium Acetate Capsules, 667mg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Mass. , Aug. 21, 2014  Decision ... COPD,  physicians in Brazil ... follow clinical guidelines and commonly prescribe long-acting beta-agonist ... although they do so within current severe cost/coverage ... (FDCs) that are expected to launch in these ...
(Date:8/21/2014)... 2014 /PRNewswire-iReach/ -- ScriptPro has been certified by ... Common Security Framework (CSF). According to Russ ... "We appreciate this rigorous, top-to-bottom audit. Security-minded customers ... certification signifies. Our business partners need to know ... CERTIFICATION PROCESS: ScriptPro,s internal security processes and controls ...
(Date:8/21/2014)... BreedIT Corp., (OTCQB: BRDT) ... worldwide license holder and distributor of highly sophisticated ... today is pleased to announce the formation of ... a leading Israeli medical Cannabis breeder. ... breeds of medical Cannabis to meet the requests ...
Breaking Medicine Technology:Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3ScriptPro Achieves HITRUST Certification 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4
... 13 An 80-year-old lung cancer patient has become ... using a new linear accelerator that can deliver precise ... Center carried out the treatment last week, becoming only ... using TrueBeam™ from Varian Medical Systems (NYSE: VAR). ...
... CANTON, Ohio, Sept. 13 AultCare has been ... in partnership with Cardiocom, released a white paper ... The paper describes the structure of ... and patient. Improved patient self-management has resulted in ...
Cached Medicine Technology:Leading Dutch Cancer Center Commences Treatments Using New TrueBeam from Varian Medical Systems 2Leading Dutch Cancer Center Commences Treatments Using New TrueBeam from Varian Medical Systems 3AultCare/Cardiocom® White Paper Shows Telehealth Services Reduce ER Visits and Inpatient Stays for Patients 2
(Date:8/21/2014)... The world wound care market is expected to ... USD 18.3 billion by 2019, posting a CAGR of ... growth include governments’ contribution to the development of wound ... ageing population. However, the growth could be restrained by ... America leads the global wound care market, with the ...
(Date:8/21/2014)... August 21, 2014 The second ... by Boston Scientific has begun in Massachusetts state ... trial. The Rottenstein Law Group LLP, a national ... claims of harm stemming from the implantation of ... for compensation for injuries suffered at http://www.wehelpwomen.com/transvaginal-mesh/ ...
(Date:8/21/2014)... 2014 Lauren Collura, a mother of two ... to the Boardwalk” Facebook sweepstakes. Lauren, her husband, and two ... beachfront house in Lavallette beginning this Saturday. , This ... sweepstakes. Last year, Horizon Blue Cross Blue Shield of New ... Sandy and decided to make it a new summer tradition. ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 The ... this year's conference will focus on the Future ... for research, innovation and commercialization. , With the ... SALSS combines the worlds' of business and science. ... widely recognized Summit, gathering a diverse community with ...
(Date:8/21/2014)... (HealthDay News) -- In a new review of seafood ... eating tuna due to concerns about mercury exposure. ... only to shrimp as the most commonly eaten seafood ... avoid all tuna," Jean Halloran, director of food policy ... Reports, said in a news release from the group. ...
Breaking Medicine News(10 mins):Health News:Global Wound Care Market to Post 3.2% CAGR Through 2019, Says MarketsandMarkets in Its New Report Published at MarketPublishers.com 2Health News:Global Wound Care Market to Post 3.2% CAGR Through 2019, Says MarketsandMarkets in Its New Report Published at MarketPublishers.com 3Health News:Transvaginal Mesh Lawsuit News: Second Boston Scientific Mesh Bellwether Trial Begins, The Rottenstein Law Group LLP Reports 2Health News:The Tenth Swedish-American Life Science Summit, takingplace in Stockholm, Sweden, August 20-22nd, will focus on The Future of Medicine 2Health News:Consumer Reports Advises Pregnant Women to Avoid Tuna 2
... get boosted by a 'super' form of an enzyme called Akt1. ... cells. These cells are also referred to as the main switch ... to attack a tumor. This was divulged in a report that ... the journal Nature Biotechnology. Researchers from Baylor College of Medicine conducted ...
... appears to be something of a great divide in terms ... Britons and their health conscious watch –what –you -eat// fellow ... worried about rocketing obesity figures that cost the NHS around ... new plan.,This involves trusts funded by them to get people ...
... magnet, that is currently used in many commercial gadgets ... implanted heart devices,// like the pacemaker, with fatal consequences. ... magnets were introduced into the market recently and are ... more familiar, dull grey iron magnets. Since the cost ...
... tennis elbow ask them to alter the grip size of ... the muscle firing patterns in the forearm demonstrates that grip ... ,Researchers apparently have "gotten a grip" on the relationship ... of the grip on the racket a player uses. ...
... who take breaks in antiretroviral (ARV) drug treatment face greater ... take their medicine regularly, according to a new study in ... end a long debate on the value of 'drug holidays', ... a popular strategy in the war against HIV and AIDS ...
... symptoms of post-traumatic stress disorder, is no more effective than ... the San Francisco VA Medical Center. ,“There was ... effects,” says lead author Thomas Neylan, MD, medical director of ... PTSD should probably stay away from this drug and others ...
Cached Medicine News:Health News:Enzyme to Boost Effect of Tumor Vaccine 2Health News:Magnets in Commercial Products may Cause a Fatal Attraction 2Health News:Tennis Elbow is Not Caused Due to Improperly Sized Tennis Racket Grip 2Health News:Tennis Elbow is Not Caused Due to Improperly Sized Tennis Racket Grip 3Health News:'Drug Holidays' Increases Death Risk in HIV Patients 2Health News:Common PTSD Drug is No More Effective Than Placebo 2
... AST (GOT) powder reagent once reconstituted offers ... liquid stability to help maximize laboratory productivity, ... turnaround time. The patented technology of the ... long shelf life and stability once reconstituted ...
LCD chart display...
... are extremely delicate and if repairs are ... can easily be damaged beyond repair and ... , On the other hand, with conscientious ... have a virtually indefinite lifespan. The very ...
Mobile offers full life cycle service for Sp02 accessories that are the vital link between pulse oximeter and patient...
Medicine Products: